Scientists have developed a new CD40 agonistic antibody to treat cancer with a different route of administration than similar drugs to date. Instead of injecting it into the bloodstream, it is injected directly into the tumors. In a small clinical trial of 12 patients with metastatic cancers, six patients had tumors shrink. Two patients experienced complete tumor remission. This immunotherapy represents a significant early result after decades of disappointment with similar drugs. Direct injection into the tumor and a new type of antibody are key changes in this approach to cancer treatment.